We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Brain Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Francesco Apicella
May 19, 2018
Counting the time from the rt,-ct concomitant treatment end's (3 tmz ajuvant cicles mean above four months from rt-ct end),considering the initial mri features and genetic profile should address from the start to a rt effect,setting the try of steroid assumption..Very hard that a neoplasm like that improves or has a recurrence in such few months from the end of a therapy,except a subtotal resection at surgery time or evident progression before rt-ct
Sanjay Dixit
May 19, 2018
Having prognostically good molecular marker in this patient, the probability of radionecrosis should be considered. The decision to biospy would depend on what radiation dose was given.The probablity of radionecrosis,however, would be low if 50.4 or54 Gy was delivered.
Initially, I would revie the initial histology, speak to radiology colleague to have further imaging with perfusion,DWI,MRS, and PET to complement the routine T1,T1 contrast,T2 images, repeat these in 6 weeks' time after giving a trial of steroids.
Apr 19, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Jose
McFaline-Figueroa
MD, PhD
Francesco Apicella
May 19, 2018
Sanjay Dixit
May 19, 2018
Apr 19, 2024
Pending Moderator approval.